Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSRT + Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
NCT07058428Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in brain metastases, lung adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Started Jun 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
brain metastaseslung adenocarcinoma
Beyond the preview
Go deeper on NCT07058428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058428.